make it possible

We invite you to participate in our financing round and become a shareholder of AbilityPharma

I want to invest

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

Media Center

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.10.2020

In the media

Ability logra financiación de la FDA y abre una ronda en Capital Cell + info
22.10.2020

In the media

Ability Pharma capta dos millones de dólares de la FDA para su ensayo clínico de páncreas + info
March

Events

BIO-Europe Spring. Paris (France) + info
February

Events

15th Biomarkers Series UK. Manchester (United Kingdom) - Marc Yeste, PhD: Pharmacodynamic biomarkers associated to ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG